Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer

Prostate

Volumn 56, Issue 1, 2003, Pages 37-44

  Chang, Bao Li ^a   Zheng, S Lilly ^a   Isaacs, Sarah D ^b   Turner, Aubrey R ^a   Bleecker, Eugene R ^a   Walsh, Patrick C ^b   Meyers, Deborah A ^a   Isaacs, William B ^b,c   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Association; Hereditary; Linkage; Prostate cancer; SRD5A2

Indexed keywords

ANDROSTANOLONE; OXIDOREDUCTASE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE TYPE 2; TESTOSTERONE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CATALYSIS; CAUCASIAN; CHROMOSOME; CLINICAL FEATURE; DISEASE ASSOCIATION; EVALUATION; FAMILIAL CANCER; GENE; GENE SEQUENCE; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SRD5A2 GENE;

AGED; CHOLESTENONE 5 ALPHA-REDUCTASE; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0037904921     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10225     Document Type: Article

References (26)

1. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP, Martin PM. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189-195.
2. Davis DL, Russell DW. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet 1993;2:820.
3. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 1995;55:3973-3975.
4. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1077-1082.
5. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-1137.
6. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001;10:185-189.
7. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000;10:407-413.
8. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-1731.
9. Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59:5878-5881.
10. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000;60:1626-1630.
11. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA, Narod SA. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001;57:199-204.
12. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001;92:683-686.
13. Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK. Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev 2002;11:417-418.
14. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12:307-312.
15. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
16. Mononen N, Ikonen T, Syrjakoski K, Matikainen M, Schleutker J, Tammela TL, Koivisto PA, Kallioniemi OP. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 2001;84:1344-1347.
17. Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C, Bujnovszky P, Bleeker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 2001;108: 335-345.
18. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): A highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-3629.
19. Weir BS. Genetic data analysis II: Methods for discrete population genetic data. Sunderland, Mass: Sinauer Association, Inc. Publishers; 1996.
20. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 1996;58:1347-1363.
21. Kong A, Cox NJ. Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 1997;61:1179-1188.
22. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Issacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-1374.
23. Ott J. Analysis of human genetic linkage. 3rd edn. Baltimore, MD: Johns Hopkins Press; 1998.
24. Whittemore A, Halpern J. A class of tests for linkage using affected pedigree members. Biometrics 1994;50:118-127.
25. Faraway JJ. Distribution of the admixture test for the detection of linkage under heterogeneity. Genet Epidemiol 1993;10:75-83.
26. Laird NM, Horvath S, Xu X. Implementing a unified approach to family based test of association. Genet Epidemiol 2000;19 (Suppl 1):36-42.